Fidelity Disruptive Medicine ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Fidelity Disruptive Medicine ETF FMED
Morningstar’s Analysis FMED
Will FMED outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 31.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Fidelity Securities Lending Cash Central Fund | 8.93 | 4M | Cash and Equivalents |
10x Genomics Inc Ordinary Shares - Class A | 4.12 | 2M | Healthcare |
Danaher Corp | 3.91 | 2M | Healthcare |
Thermo Fisher Scientific Inc | 3.63 | 2M | Healthcare |
LifeStance Health Group Inc Ordinary Shares | 3.21 | 2M | Healthcare |
argenx SE ADR | 2.93 | 1M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 2.85 | 1M | Healthcare |
Alnylam Pharmaceuticals Inc | 2.85 | 1M | Healthcare |
Cogent Biosciences Inc | 2.83 | 1M | Healthcare |
Illumina Inc | 2.50 | 1M | Healthcare |